SCHEDULE: Vanguard Group Reports 0% Krystal Biotech Ownership

The Vanguard Group has reported a 0% beneficial ownership in Krystal Biotech Inc. common stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Krystal Biotech Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Krystal Biotech Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Krystal Biotech, as the change in Vanguard's reported ownership is due to internal restructuring rather than a strategic divestment based on Krystal Biotech's performance or prospects.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently undergo internal restructurings or reallocations of reporting responsibilities, which can lead to changes in their reported beneficial ownership without necessarily reflecting a change in investment thesis for the underlying company. This disaggregated reporting aligns with SEC guidelines for large investment managers.

Key Dates

Keywords

Krystal Biotech, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management, Realignment